arGentis Pharmaceuticals, LLC Release: Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published

Published: Jun 30, 2008

MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today that the Phase II results using highly purified type 1 bovine collagen orally (now known as ARG201) in the treatment of diffuse cutaneous systemic sclerosis (scleroderma – SSc) have been published in the June issue of Arthritis & Rheumatism, a major peer-reviewed rheumatology research journal. Systemic sclerosis is an autoimmune disease causing widespread fibrosis of the skin and internal organs. ARG201 is an immunotherapy that induces low dose oral immune tolerance in SSc patients causing downregulation of the body’s autoimmune response. There are no approved treatments for the underlying cause of SSc, which has a median survival of eleven years (Mayes 2004).

Back to news